PMID- 23636221
OWN - NLM
STAT- MEDLINE
DCOM- 20140219
LR  - 20211021
IS  - 1476-5470 (Electronic)
IS  - 1466-4879 (Print)
IS  - 1466-4879 (Linking)
VI  - 14
IP  - 5
DP  - 2013 Jul-Aug
TI  - Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis 
      C virus.
PG  - 330-5
LID - 10.1038/gene.2013.25 [doi]
AB  - Human leukocyte antigen (HLA) genotype has been associated with the probability 
      of spontaneous clearance of hepatitis C virus (HCV). However, no prior studies 
      have examined whether this relationship may be further characterized by grouping 
      HLA alleles according to their supertypes, defined by their binding capacities. 
      There is debate regarding the most appropriate method to define supertypes. 
      Therefore, previously reported HLA supertypes (46 class I and 25 class II) were 
      assessed for their relation with HCV clearance in a population of 758 
      HCV-seropositive women. Two HLA class II supertypes were significant in 
      multivariable models that included: (i) supertypes with significant or borderline 
      associations with HCV clearance after adjustment for multiple tests, and (ii) 
      individual HLA alleles not part of these supertypes, but associated with HCV 
      clearance in our prior study in this population. Specifically, supertype DRB3 
      (prevalence ratio (PR)=0.4; P=0.004) was associated with HCV persistence, whereas 
      DR8 (PR=1.8; P=0.01) was associated with HCV clearance. Two individual alleles 
      (B*57:01 and C*01:02) associated with HCV clearance in our prior study became 
      nonsignificant in analysis that included supertypes, whereas B*57:03 (PR=1.9; 
      P=0.008) and DRB1*07:01 (PR=1.7; P=0.005) retained their significance. These data 
      provide epidemiologic support for the significance of HLA supertypes in relation 
      to HCV clearance.
FAU - Kuniholm, M H
AU  - Kuniholm MH
AD  - Department of Epidemiology and Population Health, Albert Einstein College of 
      Medicine, Bronx, NY 10461, USA. mark.kuniholm@einstein.yu.edu
FAU - Anastos, K
AU  - Anastos K
FAU - Kovacs, A
AU  - Kovacs A
FAU - Gao, X
AU  - Gao X
FAU - Marti, D
AU  - Marti D
FAU - Sette, A
AU  - Sette A
FAU - Greenblatt, R M
AU  - Greenblatt RM
FAU - Peters, M
AU  - Peters M
FAU - Cohen, M H
AU  - Cohen MH
FAU - Minkoff, H
AU  - Minkoff H
FAU - Gange, S J
AU  - Gange SJ
FAU - Thio, C L
AU  - Thio CL
FAU - Young, M A
AU  - Young MA
FAU - Xue, X
AU  - Xue X
FAU - Carrington, M
AU  - Carrington M
FAU - Strickler, H D
AU  - Strickler HD
LA  - eng
GR  - UO1-HD-32632/HD/NICHD NIH HHS/United States
GR  - U01 AI031834/AI/NIAID NIH HHS/United States
GR  - U01 AI035004/AI/NIAID NIH HHS/United States
GR  - 5P30AI051519-08/AI/NIAID NIH HHS/United States
GR  - P30 AI051519/AI/NIAID NIH HHS/United States
GR  - R01 AI057006/AI/NIAID NIH HHS/United States
GR  - UO1-AI-35004/AI/NIAID NIH HHS/United States
GR  - TL1 RR025748/RR/NCRR NIH HHS/United States
GR  - UO1-AI-34993/AI/NIAID NIH HHS/United States
GR  - U01 AI034994/AI/NIAID NIH HHS/United States
GR  - TL1RR025748/RR/NCRR NIH HHS/United States
GR  - R01AI057006/AI/NIAID NIH HHS/United States
GR  - P30 AI027763/AI/NIAID NIH HHS/United States
GR  - UO1-AI-42590/AI/NIAID NIH HHS/United States
GR  - UO1-AI-31834/AI/NIAID NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
GR  - UO1-AI-34994/AI/NIAID NIH HHS/United States
GR  - KL2 RR025749/RR/NCRR NIH HHS/United States
GR  - R01A1052065/PHS HHS/United States
GR  - UL1 RR025750/RR/NCRR NIH HHS/United States
GR  - UO1-AI-34989/AI/NIAID NIH HHS/United States
GR  - UL1RR025750/RR/NCRR NIH HHS/United States
GR  - UL1 RR024131/RR/NCRR NIH HHS/United States
GR  - U01 AI034989/AI/NIAID NIH HHS/United States
GR  - HHSN261200800001C/RC/CCR NIH HHS/United States
GR  - U01 AI034993/AI/NIAID NIH HHS/United States
GR  - U01 HD032632/HD/NICHD NIH HHS/United States
GR  - U01 AI042590/AI/NIAID NIH HHS/United States
GR  - KL2RR025749/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130502
PL  - England
TA  - Genes Immun
JT  - Genes and immunity
JID - 100953417
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*57:03 antigen)
RN  - 0 (HLA-DR Serological Subtypes)
RN  - 0 (HLA-DR8 antigen)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*07 antigen)
SB  - IM
MH  - Female
MH  - HLA Antigens/classification/genetics/*immunology
MH  - HLA-B Antigens/genetics/*immunology
MH  - HLA-DR Serological Subtypes/genetics/*immunology
MH  - HLA-DRB1 Chains/genetics/*immunology
MH  - Hepacivirus/*immunology
MH  - Hepatitis C/genetics/*immunology/virology
MH  - Humans
MH  - Multivariate Analysis
MH  - Review Literature as Topic
PMC - PMC3723800
MID - NIHMS462878
COIS- All authors declare no conflicts of interest.
EDAT- 2013/05/03 06:00
MHDA- 2014/02/20 06:00
PMCR- 2014/01/01
CRDT- 2013/05/03 06:00
PHST- 2012/10/10 00:00 [received]
PHST- 2013/03/14 00:00 [revised]
PHST- 2013/04/01 00:00 [accepted]
PHST- 2013/05/03 06:00 [entrez]
PHST- 2013/05/03 06:00 [pubmed]
PHST- 2014/02/20 06:00 [medline]
PHST- 2014/01/01 00:00 [pmc-release]
AID - gene201325 [pii]
AID - 10.1038/gene.2013.25 [doi]
PST - ppublish
SO  - Genes Immun. 2013 Jul-Aug;14(5):330-5. doi: 10.1038/gene.2013.25. Epub 2013 May 
      2.